Vishwa Jeet Amatya (Vishwa J Amatya)

Years Active: 2016-2023
Publications (10 Years): 5

Hiroshima University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Hiroshima University - Mar 23 2003

Japan

PHD :: Pathology

Publications

Yu Izaki, Vishwa Jeet Amatya, Takahiro Kambara, Kei Kushitani, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima
Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung. Cancers 15 (23) (2023)
Yuichiro Kai, Vishwa Jeet Amatya, Kei Kushitani, Takahiro Kambara, Rui Suzuki, Yasuhiro Tsutani, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima
Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. Histopathology 74 (4) (2019)
Vishwa Jeet Amatya, Kei Kushitani, Amany Sayed Mawas, Yoshihiro Miyata, Morihito Okada, Takumi Kishimoto, Kouki Inai, Yukio Takeshima
Reply to 'MUC4 staining in sarcomatoid carcinomas' by Berg et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 32 (1) (2018)
Amany Sayed Mawas, Vishwa Jeet Amatya, Kei Kushitani, Yuichiro Kai, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima
MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Scientific reports 8 (1) (2018)
Kei Kushitani, Vishwa Jeet Amatya, Yasuko Okada, Yuya Katayama, Amany S Mawas, Yoshihiro Miyata, Morihito Okada, Kouki Inai, Takumi Kishimoto, Yukio Takeshima
Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma. Histopathology 70 (3) (2016)

Vishwa Jeet Amatya.css-eqlu8i{font-size:small;padding-left:4px;} (Vishwa J Amatya)